• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Syneos Health Names Terttu Haring President, Clinical Sites & Patients

    9/26/23 7:30:00 AM ET
    $SYNH
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $SYNH alert in real time by email

    MORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients. With nearly 30 years of experience, Dr. Haring will lead the global clinical operations organization to drive exceptional delivery, quality and data integrity for customers, while ensuring a positive experience for sponsors, sites and patients. Her investigator background, and technology and data experience, will empower the Clinical Sites & Patients team to execute data-driven solutions that produce strong results for customers.

    Under Dr. Haring's guidance, Syneos Health will continue to nurture its heritage of scientific and therapeutic expertise across global clinical operations. Dr. Haring will also empower the Clinical Sites & Patients team to leverage the Company's in-depth local regulatory experience, with its expanding global footprint, to better connect patients and sites worldwide. Fueled by advanced data, analytics and insights from sources such as Syneos Health's Patient Voice Consortium, the team is leveraging technology and deep enterprise expertise to execute more representative clinical trial research.

    Based in Amsterdam, Netherlands, Dr. Haring's appointment adds to a growing team of global therapeutic experts at Syneos Health who design and execute fit-for-purpose solutions that deliver high-quality results for customers across the clinical to commercial continuum.

    "As the clinical trial landscape rapidly evolves, a steadfast focus on designing the best protocols, enabling sites and site networks, and empowering patients is key for successful clinical trial execution and product commercialization," said Michael Brooks, Chief Operating Officer, Syneos Health. "We are thrilled to welcome Terttu to our organization to help us advance our operating model to more effectively execute clinical operations that meet industry, customer, partner and patient needs. Her relentless focus on execution and quality will continue to build our patient-centered clinical trial solutions that enable sponsors to accelerate the development of treatments that impact patients' lives."

    With decades of pharma and CRO experience, Dr. Haring most recently held multiple leadership roles at Sanofi, with escalating responsibility across Clinical Research, Trial Operations and Data Management, and Clinical Innovation. She began her research career at Kendle International, a CRO acquired by INC Research, which then became Syneos Health.

    "I am passionate about unlocking the potential of clinical trials for all patients – leveraging digital health, data science and site productivity enhancements for optimized operations," said Dr. Haring. "I look forward to leveraging Syneos Health's vast enterprise to deliver for sponsors and bring patients and sites more actively together – meeting and anticipating the needs of all stakeholders in the clinical trial ecosystem."

    About Syneos Health

    Syneos Health® (NASDAQ:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.  

    We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. 

    Together we share insights, use the latest technologies and apply advanced business practices to speed our customers' delivery of important therapies to patients. 

    Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.  

    To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com.

    Investor Relations Contact:   Press/Media Contact:
    Ronnie Speight    Gary Gatyas
    Senior Vice President, Investor Relations  Executive Director, External Communications
    +1 919 745 2745   +1 908 763 3428
    [email protected] [email protected] 

     



    Primary Logo

    Get the next $SYNH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYNH

    DatePrice TargetRatingAnalyst
    2/13/2023$30.00 → $28.00Neutral → Underweight
    JP Morgan
    1/17/2023$30.00 → $25.00Overweight → Underweight
    Barclays
    1/13/2023$25.00Overweight → Underweight
    Barclays
    12/14/2022$66.00 → $38.00Buy → Neutral
    Mizuho
    11/7/2022$55.00 → $27.00Outperform → In-line
    Evercore ISI
    10/18/2022$85.00 → $53.00Overweight → Neutral
    JP Morgan
    9/14/2022Buy → Neutral
    Guggenheim
    9/7/2022$68.00Neutral
    UBS
    More analyst ratings

    $SYNH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Syneos Health downgraded by JP Morgan with a new price target

      JP Morgan downgraded Syneos Health from Neutral to Underweight and set a new price target of $28.00 from $30.00 previously

      2/13/23 7:39:42 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Syneos Health downgraded by Barclays with a new price target

      Barclays downgraded Syneos Health from Overweight to Underweight and set a new price target of $25.00 from $30.00 previously

      1/17/23 9:22:20 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Syneos Health downgraded by Barclays with a new price target

      Barclays downgraded Syneos Health from Overweight to Underweight and set a new price target of $25.00

      1/13/23 9:04:42 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    SEC Filings

    See more
    • SEC Form 15-12G filed by Syneos Health Inc.

      15-12G - Syneos Health, Inc. (0001610950) (Filer)

      10/10/23 6:08:58 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 8-K filed by Syneos Health Inc.

      8-K - Syneos Health, Inc. (0001610950) (Filer)

      10/3/23 8:12:59 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by Syneos Health Inc.

      S-8 POS - Syneos Health, Inc. (0001610950) (Filer)

      9/28/23 12:32:55 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.

      JERSEY CITY, N.J., April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in the United States (U.S.). In 2016, MTPA was created as a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), with the goal of developing and advancing the company's pipeline in the U.S. while focusing on improving research in the areas of amyotrophic lateral sclerosis (ALS), erythropoietic protoporphyria (EPP), Parkinson's disease, spinal cord injury and systemic sclerosis. "For almost a decade, MT

      4/29/24 9:00:00 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting

      Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight results from Phase 3 BouNDless trial in PD and real-world findings from preliminary analysis of RADICAVA® (edaravone) treatment in ALSJERSEY CITY, N.J., April 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced seven presentations will be shared at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024. The presentations will discuss four abstracts in Parkinson's disease (PD) and three in amyotrophic lateral sclerosis (ALS).

      4/12/24 9:00:00 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)

      Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care  JERSEY CITY, N.J., April 8, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that the U.S. Food and Drug Administration (FDA) has recognized seven years of Orphan Drug Exclusivity (ODE) for RADICAVA ORS® (edaravone) based on their assessment that the oral form of edaravone constitutes a major contribution to patient care for people living with amyotrophic lateral sclerosis (ALS). The FDA's Orphan Drug program is designed to support the development of drugs that treat rare diseases which affect less than 200,000 people in the U.S. Previously, the FDA granted RADIC

      4/8/24 9:00:00 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Zulueta Alfonso G returned $150,199 worth of shares to the company (8,356 units at $17.97), closing all direct ownership in the company (SEC Form 4)

      4 - Syneos Health, Inc. (0001610950) (Issuer)

      9/28/23 5:08:43 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Wilkes David S. returned $213,839 worth of shares to the company (9,836 units at $21.74), closing all direct ownership in the company (SEC Form 4)

      4 - Syneos Health, Inc. (0001610950) (Issuer)

      9/28/23 5:08:14 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Monaghan Matthew E. returned $850,411 worth of shares to the company (24,640 units at $34.51), closing all direct ownership in the company (SEC Form 4)

      4 - Syneos Health, Inc. (0001610950) (Issuer)

      9/28/23 5:07:50 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    Leadership Updates

    Live Leadership Updates

    See more
    • NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

      2/27/24 9:00:00 AM ET
      $BMRN
      $ENOV
      $OPCH
      $SYNH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Civitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600

      NEW YORK, Sept. 26, 2023 /PRNewswire/ -- S&P SmallCap 600 constituent Civitas Resources Inc. (NYSE:CIVI) will replace Syneos Health Inc. (NASD: SYNH) in the S&P MidCap 400, and Hayward Holdings Inc. (NYSE:HAYW) will replace Civitas Resources in the S&P SmallCap 600 effective prior to the opening of trading on Friday, September 29. Elliot Investment Management is acquiring Syneos Health in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector September 29, 2023 S&P MidCap 400 Addition Civitas Resources

      9/26/23 5:41:00 PM ET
      $CIVI
      $HAYW
      $SPGI
      $SYNH
      Oil & Gas Production
      Energy
      Industrial Machinery/Components
      Industrials
    • Syneos Health Names Terttu Haring President, Clinical Sites & Patients

      MORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients. With nearly 30 years of experience, Dr. Haring will lead the global clinical operations organization to drive exceptional delivery, quality and data integrity for customers, while ensuring a positive experience for sponsors, sites and patients. Her investigator background, and technology and data experience, will empower the Clinical Sites & Patients team to execute data-driven solutions that produce strong results for customers. Under Dr. Haring'

      9/26/23 7:30:00 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    Financials

    Live finance-specific insights

    See more
    • Syneos Health Stockholders Approve Agreement with Private Investment Consortium

      MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company's stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier today. As previously announced, under the terms of the agreement, Syneos Health stockholders will receive $43.00 in cash for each share of Syneos Health common stock owned at the closing o

      8/2/23 8:47:45 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Syneos Health to be Acquired by a Private Investment Consortium for Approximately $7.1 Billion

      Shareholders to Receive $43.00 Per Share in Cash Represents 24% Premium to Unaffected Stock Price MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (NASDAQ:SYNH) ("Syneos Health" or the "Company"), a leading fully integrated biopharmaceutical solutions organization, today announced that it has entered into a definitive agreement to be acquired by a consortium of private investment firm affiliates composed of Elliott Investment Management ("Elliott"), Patient Square Capital ("Patient Square"), and Veritas Capital ("Veritas") for $43.00 per share in cash in a transaction valued at approximately $7.1 billion, including outstanding debt. The purchase price represents a

      5/10/23 6:47:41 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Syneos Health Schedules First Quarter 2023 Earnings Call for Wednesday, May 10th, 2023

      MORRISVILLE, N.C., April 13, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, will release its first quarter 2023 financial results on Wednesday, May 10th, 2023, prior to its earnings call at 8:00 a.m. ET. To listen only and view the presentation slides via the live webcast, join from the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate in the conference, please register in advance at this link. Upon registration, all participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uni

      4/13/23 4:31:00 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SYNH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Syneos Health Inc. (Amendment)

      SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)

      6/9/23 10:14:20 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Syneos Health Inc. (Amendment)

      SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)

      2/6/23 2:58:20 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Syneos Health Inc. (Amendment)

      SC 13G/A - Syneos Health, Inc. (0001610950) (Subject)

      1/23/23 3:52:32 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care